Bio-Techne (TECH) Receivables (2010 - 2026)

Bio-Techne's Receivables history runs 17 years deep, the most recent figure standing at $214.6 million for Q1 2026.

• On a quarterly basis, Receivables fell 9.52% year-over-year to $214.6 million in Q1 2026; TTM through Mar 2026 was $214.6 million, a 9.52% decrease from a year earlier, with the FY2025 full-year figure at $206.9 million, down 14.3% from the prior year.
• Receivables rose to $214.6 million in Q1 2026 per TECH's latest filing, from $184.6 million in the prior quarter.
• Across five years, Receivables topped out at $241.4 million in Q2 2024 and bottomed at $174.2 million in Q3 2022.
• The 5-year median for Receivables is $207.5 million (2023), against an average of $208.3 million.
• Across the five-year window, Receivables surged 33.82% in 2022 and fell 17.79% in 2025, its largest moves.
• Year by year, Receivables stood at $184.8 million in 2022, then gained by 12.28% to $207.5 million in 2023, then climbed by 5.06% to $217.9 million in 2024, then dropped by 15.29% to $184.6 million in 2025, then rose by 16.22% to $214.6 million in 2026.
• Per Business Quant, the three latest TECH Receivables figures stand at $214.6 million (Q1 2026), $184.6 million (Q4 2025), and $183.9 million (Q3 2025).